5-氨基-1-Boc-苯并咪唑 | 297756-31-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-氨基-1-Boc-苯并咪唑
• 中文别名: N-Boc-5-氨基苯并咪唑
• 英文名称: tert-butyl 5-amino-1H-benzo[d]imidazole-1-carboxylate
• 英文别名: tert-butyl 5-aminobenzimidazole-1-carboxylate
• CAS: 297756-31-1
• 化学式: C₁₂H₁₅N₃O₂
• 分子量: 233.27
• InChiKey: XDHCBTYFHVDHFD-UHFFFAOYSA-N

物化性质

• 沸点：
  397.4±34.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-氨基-1-Boc-苯并咪唑 、 1-(3-isothiocyanatopropyl)-5-methyl-1H-imidazole 在 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 tert-butyl 5-(3-(3-(5-methyl-1H-imidazol-1-yl)propyl)thioureido)-1H-benzo[d]imidazole-1-carboxylate
  参考文献：
  名称：

  Structure–activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template

  摘要：

  In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-A beta and A beta plaques in cells and transgenic animals. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.04.005
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 5-氨基苯并咪唑 在 sodium hydride 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 19.0h， 生成 5-氨基-1-Boc-苯并咪唑 、 tert-butyl 6-amino-1H-benzo[d]imidazole-1-carboxylate
  参考文献：
  名称：

  3-(anilinomethylene) oxindoles

  摘要：

  本发明一般涉及新型胺取代的噁二酮化合物和组合物。这些化合物和组合物作为药理学药剂在治疗由于一般蛋白激酶激活的信号通路的抑制或拮抗而减轻的疾病或症状方面具有实用性，特别是在涉及异常细胞增殖的病理过程中，如肿瘤生长。具体而言，本发明涉及一系列取代的噁二酮化合物，其表现出蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶抑制作用，并且在通过抑制与肿瘤相关的血管生成抑制肿瘤生长方面是有用的。

  公开号：

  US06350747B1

文献信息

• NOVEL INHIBITORS
  申请人：Heiser Ulrich

  公开号：US20110262388A1

  公开（公告）日：2011-10-27

  Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

  新型杂环衍生物作为谷氨酰胺环化酶（QC，EC 2.3.2.5）的抑制剂。QC催化N-末端谷氨酸残基的分子内环化，生成丙氨酸内酰胺（5-氧代脯氨酰，pGlu*），同时释放氨气，以及N-末端谷氨酸残基的分子内环化，生成丙氨酸内酰胺，同时释放水。
• FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME
  申请人：Ashikawa Masanori

  公开号：US20120108581A1

  公开（公告）日：2012-05-03

  The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula (1): (wherein, ring A represents a C 10-14 aryl group or 5- to 10-membered heterocyclic group, X represents N—R 7 , a sulfur atom or an oxygen atom, R 1 , R 2 , R 2′ , R 3 and R 3′ independently represent a hydrogen atom, C 1-6 alkyl group or C 3-6 cycloalkyl group, and R 4 , R 5 and R 6 independently represent a hydrogen atom or halogen atom), or a salt thereof, or a solvate thereof.

  本发明提供了一种低分子量化合物，具有促进EPO产生和/或促进血红蛋白产生的作用。本发明涉及一种融合哌啶化合物，其表示为以下通式（1）： （其中，环A表示C10-14芳基或5-至10元杂环基，X表示N-R7，硫原子或氧原子，R1、R2、R2'、R3和R3'独立地表示氢原子、C1-6烷基或C3-6环烷基，而R4、R5和R6独立地表示氢原子或卤素原子），或其盐或溶剂化物。
• Fused piperidine compound and pharmaceutical containing same
  申请人：Ashikawa Masanori

  公开号：US08604030B2

  公开（公告）日：2013-12-10

  The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula (1): (wherein, ring A represents a C10-14 aryl group or 5- to 10-membered heterocyclic group, X represents N—R7, a sulfur atom or an oxygen atom, R1, R2, R2′, R3 and R3′ independently represent a hydrogen atom, C1-6 alkyl group or C3-6 cycloalkyl group, and R4, R5 and R6 independently represent a hydrogen atom or halogen atom), or a salt thereof, or a solvate thereof.

  本发明提供了一种具有促进EPO产生和/或促进血红蛋白产生作用的低分子量化合物。本发明涉及由下述通式（1）表示的融合哌啶化合物：（其中，环A表示C10-14芳基或5-至10元杂环基，X表示N—R7、硫原子或氧原子，R1、R2、R2′、R3和R3′独立地表示氢原子、C1-6烷基或C3-6环烷基，而R4、R5和R6独立地表示氢原子或卤素原子），或其盐或其溶剂化物。
• Inhibitors
  申请人：Heiser Ulrich

  公开号：US08541596B2

  公开（公告）日：2013-09-24

  Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

  新型杂环衍生物作为谷氨酰环化酶（QC，EC 2.3.2.5）的抑制剂。QC催化N-末端谷氨酰残基向内环化成为吡二酰氨基酸（5-氧代-脯氨酰基，pGlu*），并释放氨，以及N-末端谷氨酸残基向内环化成为吡二酰氨基酸，并释放水。
• FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME
  申请人：Kowa Company, Ltd.

  公开号：EP2412710A1

  公开（公告）日：2012-02-01

  The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula (1): (wherein, ring A represents a C10-14 aryl group or 5- to 10-membered heterocyclic group, ring B represents a C6-14 alkyl group, X represents N-R7, a sulfur atom or an oxygen atom, R1, R2, R2', R3 and R3' independently represent a hydrogen atom, C1-6 alkyl group or C3-6 cycloalkyl group, and R4, R5 and R6 independently represent a hydrogen atom or halogen atom), or a salt thereof, or a solvate thereof.

  本发明提供了一种具有促进EPO生成作用和/或促进血红蛋白生成作用的低分子量化合物。本发明涉及一种由以下通式（1）代表的融合哌啶化合物： (其中，环A代表C10-14芳基或5-10元杂环基，环B代表C6-14烷基，X代表N-R7、硫原子或氧原子，R1、R2、R2'、R3和R3'独立地代表氢原子、C1-6烷基或C3-6环烷基，R4、R5和R6独立地代表氢原子或卤素原子），或其盐，或其溶液。